Under construction – not a live service
Sign in
Not yet taking people in ChinaPhase 1/2

Tests CAR T cell therapy in adults with relapsed or hard-to-treat multiple myeloma

Tests immune cells modified to attack several myeloma targets, in adults with relapsed myeloma.

Key facts

Who runs it
Shenzhen Geno-Immune Medical Institute
Where
Shenzhen, ChinaSee the site
Trial code
Registry title
Multi-CAR T Cell Therapy in the Treatment of Multiple Myeloma
Status
Not yet recruiting
Phase
Phase 1/2
People taking part
20 people, planned
Starts
31 Dec 2026
Expected to end
31 Dec 2030
Type of study
Interventional
Treatments tested
  • CAR T cells
Record updated
30 October 2026

Who can take part

AI summary

From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.

The trial is looking for adults with multiple myeloma that came back or did not respond to treatment, and who have no other treatment that could remove the disease.

Age
18 Years to 80 Years
Sex
Men and women can join.
Disease stage
Multiple myeloma with a confirmed surface antigen, where no other treatment meant to remove all of the disease is available. Complete remission could not be reached after at least 4 earlier combination treatments, or the disease came back after a stem cell transplant, or the disease remains after first treatment and a transplant is not possible.
Earlier treatment
At least 4 earlier combination treatments without complete remission, or at least 1 earlier treatment for relapsed or remaining disease. Some people have had a stem cell transplant. Less than 1 year between the last chemotherapy and progression. No earlier related CAR-T cell therapy.
Biomarker or test result
Multiple myeloma cells with a confirmed surface antigen. Creatinine < 2.5 mg/dl (221 µmol/L), ALT/AST < 3x normal, bilirubin < 2.0 mg/dl.

Main reasons for not taking part

  • Pregnant or breastfeeding women
  • Uncontrolled active infection
  • Active hepatitis B or hepatitis C infection
  • HIV infection
  • Current use of systemic steroids

The registry criteria, word for word

Show all 19 criteriaShow less

Who can take part

  • Male and female subjects with surface antigen confirmed multiple myeloma with no available curative treatment options (including autologous or allogeneic SCT)
  • Complete remission (CR) cannot be achieved after at least 4 prior combination therapy regimens
  • MM in CR2 or CR3 and not eligible for allogeneic SCT because of age, comorbid diseases, or lack of available donor
  • Less than 1 year between last chemotherapy and progression (i.e. most recent progression free interval < 1 year)
  • Relapsed after prior autologous or allogenic SCT MM patients with relapsed or residual disease after at least 1 prior therapy and not eligible for allogeneic SCT
  • Residual disease after primary therapy and not eligible for ASCT
  • Expected survival > 12 weeks
  • Creatinine < 2.5 mg/dl
  • ALT (alanine aminotransferase)/AST (aspartate aminotransferase) < 3x normal
  • Bilirubin < 2.0 mg/dl
  • Any relapse after prior SCT is eligible regardless of other prior therapy
  • Adequate venous access for apheresis, and no other contraindications for leukapheresis
  • Voluntary informed consent is given

Who cannot take part

  • Concurrent use of systemic steroids. Recent or current use of inhaled steroids is not exclusionary
  • Previous related CAR-T cell therapy Any uncontrolled active medical disorder that would preclude participation
  • Uncontrolled active infection
  • Active hepatitis B or hepatitis C infection
  • HIV infection
  • Pregnant or lactating women

Check if you might fit

Answer for yourself. This is not a decision: only the study team can say whether you can take part.

  • Are you between 18 and 80 years old?

Where in China

  • Shenzhen Geno-immune Medical InstituteShenzhen, ChinaContact: Lung-Ji Chang, PhDNo longer taking part

About the trial

What the trial wants to find out

The aim of this clinical trial is to assess the feasibility, safety and efficacy of autologous CAR T cell immunotherapy targeting multiple cancer cell surface antigens in relapsed and refractory multiple myeloma patients. Another goal of the study is to learn more about the persistence and function of CAR T cells in the body.

The group in the trial

  • Single armTreatment being tested

    CAR T cells to treat MM

    Treatment: CAR T cells

Questions to ask the study team

  1. How often do I need to come in, and for how long each time?
  2. Are travel costs paid?
  3. Can I keep my own doctor?
  4. What happens if I want to stop?

Contact the study team: see the registry record → Contacts and Locations

Print a page for my doctor

Data and sources

Registry record
Listed on ClinicalTrials.gov.
Official title
Multiple Antigen-specific CAR T Cells For the Treatment of Multiple Myeloma
Plain-language title
Tests CAR T cell therapy in adults with relapsed or hard-to-treat multiple myelomaGenerated from the registry record. The registry title is the official one.
AI summary
From the trial's eligibility criteria. Read by machine on 12 November 2026.
Fit questions
Built from NCT03271632, who can take part
Record updated
30 October 2026